Evolus, Inc. (EOLS)
Evolus, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Newport Beach, CA, US. The stock last traded at $8.28, down 0.72% on the session, giving a market capitalisation of $545.3M. On trailing twelve-month figures it carries a trailing P/E of -15.98, a net margin of -10.8%. Its beta of 1.36 implies it has historically moved more than the broad market.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Evolus, Inc. is most often compared with the following Healthcare names: